HDx 高清洗血

Expanded haemodialysis (HDx) 高清洗血 can make a world of difference for patients, clinicians and healthcare systems.

Haemodialysis (HD): when your natural filters need help.

Your kidneys work 24/7 to filter out toxins and excess water from your blood through the production of urine. If you have chronic kidney disease (CKD) at the later stages, your kidneys lose their ability to remove waste and fluid from the body. Harmful waste and fluids accumulate, causing you to feel unwell. When this happens, your doctor might have talked to you about haemodialysis (HD), a renal replacement treatment alternate to peritoneal dialysis (PD) that can help you feel better by using an artificial kidney (dialysis machine).

How does HD work?

During haemodialysis (HD), an HD machine removes a small amount of blood from your body through a needle or catheter. The dialyser in the machine then filters your blood, removing waste, toxins, and excess fluid before returning your filtered blood to your body.

Hemodialysis is done in a clinic 2 to 3 times a week as prescribed by healthcare professionals.

Uremic Toxin Classes by molecular weight (Daltons)

What are the toxins that need to be filtered out during dialysis?

The types of uremic toxins that accumulate in your body when the kidneys are impaired are classified based on their size, as shown in the diagram.

Unlike our natural kidneys, current HD therapy has some limitations in removing large-middle molecule uremic toxins. It is estimated that more than 50 types of large-middle uremic toxins are present in human blood. ¹These large-middle molecules can contribute various health side-effects like inflammation cardiovascular health, restless leg syndrome and other dialysis-related co-morbidities.

Are you suffering from any of these symptoms?
Your current haemodialysis may not be enough.

CARPAL TUNNEL SYNDROME (CTS)

UREMIC PRURITUS

FATIGUE & LONG RECOVERY TIME

Feeling extremely tired for more than 2 hours after HD session ⁷
Poor quality of life, difficulty in managing daily activities, stress from dialysis treatment and increased risk of hospitalisation and death.^7,8
Frequency in patients on chronic haemodialysis: 68% ⁷
A build-up of Interleukin-6 (IL-6) a medium-middle-sized uremic toxin associated with elevated inflammation risk, could be a cause. ⁹

RESTLESS LEGS SYNDROME (RLS)

20% of patients with end-stage kidney failure will have RLS ^10-11, a neurological condition characterised by an irresistible urge to move the limbs accompanied by uncomfortable sensations. ¹²
This may cause poor quality of life, depression, muscle atrophy, impaired sleep, and increased risk of cardiovascular disease and mortality. ¹²
a1-Microglobulin (large-middle molecule) is associated with restless legs syndrome and high mortality.¹³

A change in filter can change your life: getting closer to the power of your natural kidneys with HDx ^14-18

HDx patient having fun with grandson enjoying good health

During haemodialysis, the dialyser in the HD machine (a filter with thousands of tiny hollow fibres with very small holes) acts as the kidney. Your blood will travel through these fibres, and different sizes of uremic toxins will be filtered out based on the size of the holes on the surface of these fibre membranes.¹ HDx is a novel type of HD treatment that uses a new and patented type of dialyser with a fiber membrane which is a step closer to our natural kidneys and designed to target the efficient removal of large-middle molecules. Removing these molecules may keep you healthier, especially if you will be on HD for a number of years.

Filter out more toxins and get more out of life

Expanded haemodialysis (HDx) is a therapy that efficiently removes large-middle molecules¹⁵ and may reduce the side effects of conventional HD therapy. ^16,17

HDx helps in:

Alleviating uremic pruritus ³
Reduce dialysis recovery time and improve perceived fatigue level ¹³
Prevent discomfort associated with restless legs syndrome ¹⁴

Feel the clear difference with HDx 高清洗血. Speak to your doctor and nurse to discover how HDx may make A WORLD OF DIFFERENCE for you!

References

Wolley M, et al. Clin J Am Soc Nephrol. 2018;13:805-814.
Kopeć J, Gadek A, Drozdz M, et al. Carpal tunnel syndrome in hemodialysis patients as a dialysis-related amyloidosis manifestation--incidence, risk factors and results of surgical treatment. Med Sci Monit. 2011;17(9):CR505-CR509. doi:10.12659/msm.881937
Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep. 2020;10(1):1-11.
Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495-3505.
Kimmel, M, Alscher DM, Dunst R, Braun, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrology Dialysis Transplantation. 2006;21(3):749-755.
Su H, Lei C.T, Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol. 2017;8:405.
Rayner HC, Zepel L, Fuller DS, et al. Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2014;64:86–94.
Bossola M, Di Stasio E, Monteburini T, et al. Recovery Time after Hemodialysis Is Inversely Associated with the Ultrafiltration Rate. Blood Purif. 2019;47(1-3):45-51.
Bossola M, Di Stasio E, Giungi S, Rosa F, Tazza L. Fatigue is associated with serum interleukin-6 levels and symptoms of depression in patients on chronic hemodialysis. J Pain Symptom Manag. 2015;49:578–585.
Lin XW, Zhang JF, Qiu MY, et al. Restless legs syndrome in end stage renal disease patients undergoing hemodialysis. BMC Neurol. 2019.19:47.
Freire de Menezes A, et al. Int J Nephrol. 2018;25;2018:1414568.
Giannaki CD, et al. Epidemiology, impact and treatment options of restless legs syndrome in end-stage renal disease patients; an evidence based review. Kidney Int. 2014;85(6):1275-1282.
Olsson M.G, Allhorn M, Bulow L, et al. Pathological conditions involving extracellular hemoglobin molecular mechanisms, clinical significance, and novel therapeutic opportunities for alpha-1-microglobulin. Antioxid Redox Signal. 2012;17:813–846.
Bolton S, Gair R, Nilsson LG, Matthews M, Stewart L, McCullagh N. Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Hemodialysis Therapy Mode. Patient Relat Outcome Meas. 2021;12:315-321.
Alarcon J.C, Bunch A, Ardila F, et al. Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry. Blood Purif. 2021;50:110-118.
Ronco, C. The Rise of Expanded Hemodialysis. Blood Purif. 2017:44:I-VIII.
Molano-Trivino A, Sanabria M, Vesga J, Buitrago G, Sanchez R, Rivera A. Effectiveness of medium cut-off vs high flux dialyzers: a propensity score matching cohort study. In Nephrol Dial Transport. 2021;36:486-U948.
Penny JD, Jarosz P, Salerno FR, Lemoine S, McIntyre CW. Impact of Expanded Hemodialysis Using Medium Cut-off Dialyzer on Quality of Life: Application of Dynamic Patient-Reported Outcome Measurement Tool. Kidney Medicine. 2021;3(6):992-1002.
Sakurai K. Biomarkers for Evaluation of Clinical Outcomes of Hemodiafiltration. Blood Purif. 2013;35(1):64-68.
Lorenz G, Schmalenberg M, Kemmner S, et al. Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation. Kidney Int. 2018;93(1):221-230.